| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,200 | 6,000 | 09.09. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 9,500 | 175 | |||
| 6,350 | 500 | |||
| 5,750 | 684 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 684 | 5,400 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 110 | 4,700 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.855 | 0,670 | 1.913 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 10:30:21 | 5,600 | 99 |
| Tagesumsatz Xetra | 0,000 0,00 % | 99 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | 548 | PR Newswire | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
PR Newswire
LONDON, United Kingdom, September 07
4basebio... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 27.08. | Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors | 22 | Contract Pharma | ||
| 26.08. | 4basebio shares jump on new marketing tie-up with US-based Genezen | 9 | Alliance News | ||
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 355 | GlobeNewswire (Europe) | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through... ► Artikel lesen | |
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 267 | PR Newswire | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Notice of Extra General Meeting in Biovica International AB | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 9, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"),... ► Artikel lesen | |
| Mi | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | Small- & Micro Cap Investment | ||
| Mi | Brain Biotech erhält 11,5 Millionen Euro - hoher Buchungseffekt belastet | 4investors | Brain Biotech erhält von Royalty Pharma eine Meilensteinzahlung von 11,51 Millionen Euro. Auslöser ist ein Entwicklungsfortschritt beim Pharmawirkstoff Deucrictibant auf Basis der 2024 geschlossenen... ► Artikel lesen | |
| Mi | OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients | GlobeNewswire (Europe) | Nantes, France, September 9, 2026 - 6pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company") welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that... ► Artikel lesen | |
| Mi | Bullion Gold Discoveries Corp.: Bullion Gold Returns 22.2 g/t Au + 24.5 g/t Ag over 1 metre in Channel R21 at Terragold | Newsfile | Montreal, Quebec--(Newsfile Corp. - September 9, 2026) - Bullion Gold Discoveries Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to announce the final results of its channel sampling program... ► Artikel lesen |